In our analysis, we discovered that the plasma pre-melanosome protein PMEL, antigen for HMB-45, demonstrates good differential (AUC of TSC vs. CY: 0.98; AUC of TSC vs. AML: 0.80) and prognostic ability (AUC of Post vs. Pre TSC: 0.72), as depicted in Table 2. This evidence concerns the gene PMEL and acute myeloid leukemia.